Morgan Stanley
PLX icon

Morgan Stanley’s Protalix BioTherapeutics PLX Stock Holding History

Morgan Stanley’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$655K Buy
301,793
+169,806
+129% +$421K ﹤0.01% 5342
2025
Q4 		$238K Buy
131,987
+60,950
+86% +$125K ﹤0.01% 5862
2025
Q3 		$158K Sell
71,037
-391,006
-85% -$637K ﹤0.01% 5977
2025
Q2 		$684K Buy
462,043
+378,485
+453% +$774K ﹤0.01% 5306
2025
Q1 		$214K Sell
83,558
-86,658
-51% -$207K ﹤0.01% 5702
2024
Q4 		$320K Buy
170,216
+127,158
+295% +$180K ﹤0.01% 5605
2024
Q3 		$43.9K Sell
43,058
-44,086
-51% -$46.4K ﹤0.01% 6259
2024
Q2 		$102K Sell
87,144
-85,927
-50% -$102K ﹤0.01% 5956
2024
Q1 		$218K Sell
173,071
-325,929
-65% -$487K ﹤0.01% 5707
2023
Q4 		$888K Buy
499,000
+300,165
+151% +$467K ﹤0.01% 5350
2023
Q3 		$330K Buy
198,835
+61,538
+45% +$110K ﹤0.01% 5345
2023
Q2 		$275K Buy
137,297
+55,121
+67% +$131K ﹤0.01% 5503
2023
Q1 		$173K Buy
82,176
+73,959
+900% +$130K ﹤0.01% 5774
2022
Q4 		$11.3K Hold
8,217
– – ﹤0.01% 6889
2022
Q3 		$9K Hold
8,217
– – ﹤0.01% 7116
2022
Q2 		$9K Sell
8,217
-15,700
-66% -$18.4K ﹤0.01% 7250
2022
Q1 		$25K Sell
23,917
-1,269,046
-98% -$1.16M ﹤0.01% 7046
2021
Q4 		$1.07M Sell
1,292,963
-992,112
-43% -$1.04M ﹤0.01% 5018
2021
Q3 		$3.04M Buy
2,285,075
+423,256
+23% +$643K ﹤0.01% 4212
2021
Q2 		$3.56M Buy
1,861,819
+1,861,769
+3,723,538% +$6.41M ﹤0.01% 4127
2021
Q1 		$0 Hold
50
– – ﹤0.01% 7540
2020
Q4 		$0 Hold
50
– – ﹤0.01% 7092
2020
Q3 		$0 Buy
+50
New +$181 ﹤0.01% 6806
2020
Q2 		– Sell
-10
Closed – – 6692
2020
Q1 		$0 Hold
10
– – ﹤0.01% 6670
2019
Q4 		$0 Sell
10
-38
-79% -$94 ﹤0.01% 6733
2019
Q3 		$0 Hold
48
– – ﹤0.01% 6722
2019
Q2 		$0 Buy
48
+10
+26% +$42 ﹤0.01% 6713
2019
Q1 		$0 Hold
38
– – ﹤0.01% 6675
2018
Q4 		$0 Hold
38
– – ﹤0.01% 6693
2018
Q3 		$0 Sell
38
-2,950
-99% -$14.8K ﹤0.01% 6773
2018
Q2 		$13K Sell
2,988
-952
-24% -$4.23K ﹤0.01% 6242
2018
Q1 		$21K Sell
3,940
-7,750
-66% -$51K ﹤0.01% 6115
2017
Q4 		$77K Sell
11,690
-463
-4% -$3.12K ﹤0.01% 5720
2017
Q3 		$71K Sell
12,153
-2,032
-14% -$13K ﹤0.01% 5673
2017
Q2 		$119K Buy
14,185
+10,195
+256% +$95.7K ﹤0.01% 5569
2017
Q1 		$54K Buy
3,990
+3,880
+3,527% +$34.9K ﹤0.01% 5807
2016
Q4 		$0 Hold
110
– – ﹤0.01% 6554
2016
Q3 		$1K Hold
110
– – ﹤0.01% 6437
2016
Q2 		$1K Hold
110
– – ﹤0.01% 6439
2016
Q1 		$1K Sell
110
-11,484
-99% -$98.4K ﹤0.01% 6480
2015
Q4 		$118K Sell
11,594
-5,281
-31% -$53.7K ﹤0.01% 5318
2015
Q3 		$199K Sell
16,875
-3,176
-16% -$50.5K ﹤0.01% 5085
2015
Q2 		$391K Buy
20,051
+4,377
+28% +$90.8K ﹤0.01% 4880
2015
Q1 		$278K Sell
15,674
-530
-3% -$10.4K ﹤0.01% 5021
2014
Q4 		$298K Buy
16,204
+2,422
+18% +$52K ﹤0.01% 5011
2014
Q3 		$334K Buy
13,782
+7,895
+134% +$227K ﹤0.01% 4837
2014
Q2 		$215K Buy
5,887
+435
+8% +$17.5K ﹤0.01% 5110
2014
Q1 		$249K Buy
5,452
+5,185
+1,942% +$242K ﹤0.01% 5004
2013
Q4 		$10K Buy
+267
New +$11.2K ﹤0.01% 6048
2013
Q3 		– Sell
-4,753
Closed -$233K – 5369
2013
Q2 		$233K Buy
+4,753
New +$252K ﹤0.01% 4751

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley's PLX Position: Q1 2026 in Review

Morgan Stanley increased its Protalix BioTherapeutics (PLX) stake by 129% in Q1 2026, buying an estimated $421K and bringing the position to 301,793 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #5342.

Morgan Stanley first reported a position in PLX in Q2 2013 and has held it in 50 quarters since. The position peaked at $3.56M in Q2 2021. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Morgan Stanley held 301,793 shares of Protalix BioTherapeutics worth $655K as of Q1 2026.
  • Morgan Stanley bought 169,806 Protalix BioTherapeutics shares in Q1 2026, an estimated $421K.
  • Protalix BioTherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5342 holding.
  • Morgan Stanley first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 50 quarters since.
  • Morgan Stanley's Protalix BioTherapeutics position peaked at $3.56M in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.